Optain is a global medical device and software company focused on revolutionizing healthcare through AI-powered clinical support tools. Their technology harnesses AI-enabled algorithms to analyze full-color retinal images to screen for referable diseases, including eye diseases and cardiovascular conditions, aiming to provide early detection and improve patient outcomes.

The company's flagship product is the Eyetelligence Assure Software & Portable Automatic Fundus Camera Turnkey Solution. This all-in-one ready-to-use package allows clinicians to quickly capture and analyze high-quality retinal images for early signs of eye diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration, as well as cardiovascular disease risk screening depending on the software option. The solution integrates easily into clinical workflows, streamlining disease screening and enhancing decision-making to improve patient care.

Optain envisions a future where everyone has access to early detection of chronic diseases through fast, non-invasive retinal screening. The company aims to deliver accuracy, affordability, and reliability without compromise, helping clinicians act sooner and safeguard patient quality of life while improving practice efficiency.

The company is founded and led by a team of clinicians, scientists, engineers, and business leaders, including world-renowned ophthalmology AI expert Professor Mingguang He, who serves as Chief Medical Officer. The leadership team combines expertise in clinical affairs, regulatory affairs, business development, product management, operations, and AI research to drive innovation and market success.

Optain is backed by leading researchers, clinicians, and industry partners such as Northwell Health, Aegis Ventures, and Ascertain.